University of California, Irvine researchers have identified the chemical switch that triggers the genetic mechanism regulating our internal body clock.
The finding, which uncovers the most specific information about the body’s circadian rhythms to date, identifies a precise target for new pharmaceuticals that can treat sleep disorders and a host of related ailments. The study appears in the Dec. 13 issue of Nature.
Paolo Sassone-Corsi, Distinguished Professor and Chair of Pharmacology, found that a single amino acid activates the genes that regulate circadian rhythms. Amino acids are the building blocks of proteins, and Sassone-Corsi was surprised to find that only a single amino acid activates the body-clock mechanism because of the complex genes involved.
“Because the triggering action is so specific, it appears to be a perfect target for compounds that could regulate this activity,” Sassone-Corsi said. “It is always amazing to see how molecular control is so precise in biology.”
Circadian rhythms are the body’s intrinsic time-tracking system, which anticipates environmental changes and adapts to the appropriate time of day. They regulate a host of body functions, from sleep patterns and hormonal control to metabolism and behavior. About 10 percent to 15 percent of all human genes are regulated by circadian rhythms. Disruption of these rhythms can profoundly influence human health and has been linked to insomnia, depression, heart disease, cancer and neurodegenerative disorders.
The gene CLOCK and its partner BMAL1 trigger circadian rhythms. Sassone-Corsi and his research team discovered last year that CLOCK functions as an enzyme that modifies chromatin, the protein architecture of a cell’s DNA.
In this current study, the Sassone-Corsi team learned that a single amino acid in the BMAL1 protein undergoes a modification that triggers the genetic chain of events involved with circadian rhythms.
Sassone-Corsi notes that if this amino-acid modification is impaired in any way, the switching mechanism can be thrown off, which can be the genetic underpinning of circadian-rhythm-related ailments. Currently, Sassone-Corsi is testing antibodies that can target this BMAL1 amino-acid activity.
Jun Hirayama, Saurabh Sahar, Benedetto Grimaldi and Yasukazu Nakahata of UC Irvine, and Teruya Tamaru and Ken Takamatsu of Toho University in Tokyo participated in the study, which received support from the Cancer Research Coordinating Committee of the University of California and the National Institutes of Health.
About the University of California, Irvine: The University of California, Irvine is a top-ranked university dedicated to research, scholarship and community service. Founded in 1965, UCI is among the fastest-growing University of California campuses, with more than 27,000 undergraduate and graduate students and about 1,800 faculty members. The second-largest employer in dynamic Orange County, UCI contributes an annual economic impact of $3.7 billion. For more UCI news, visit www.today.uci.edu.
Television: UCI has a broadcast studio available for live or taped interviews. For more information, visit www.today.uci.edu/broadcast.
News Radio: UCI maintains on campus an ISDN line for conducting interviews with its faculty and experts. The use of this line is available free-of-charge to radio news programs/stations who wish to interview UCI faculty and experts. Use of the ISDN line is subject to availability and approval by the university.